相关实验视频

Updated: Jul 5, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

针对低级质瘤免疫治疗的预测小组

Qingqing Lv¹, Zhaoyu Zhang¹, Haijuan Fu¹

¹Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China; The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.

World neurosurgery

|January 12, 2024

概括

这项研究确定了低度质瘤 (LGG) 中的三个免疫亚型. 患有IS2亚型的患者最适合免疫疗法,有五种特定标记物预测治疗成功.

科学领域:

神经瘤学神经瘤学
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

低级质瘤 (LGG) 治疗依赖于手术,放射治疗和化疗,面临副作用和耐药性等局限性.
免疫疗法对LGG很有前途,但由于瘤微环境和瘤抗原表达的限制,通常会受到阻碍.

研究的目的:

为了确定在LGG中免疫检查点治疗的最佳候选患者.
探索免疫特征,并确定LGG免疫疗法疗效的预测标志物.

主要方法:

综合RNA测序数据和临床信息,用于一致的集群分析.
使用了基因组丰富,UMAP,突变相关性,TIMER和TIDE分析.
分析了同源复合修复 (HRR) 基因突变和跨亚型的免疫细胞透.

主要成果:

确定了三种不同的免疫亚型 (IS1,IS2,IS3) 与分离的HRR基因突变.
IS2亚型呈现出高HRR突变和上调免疫检查点基因,表明免疫性增加和适合免疫治疗.
发现了五个预测标记 (NAMPT,SLC11A1,TNC,VIM,SPP1) 免疫检查点阻塞 (ICB) 在LGG中的有效性,与预后相关.

结论:

确立了三种可靠的LGG免疫亚型,IS2患者是免疫治疗的理想候选人.
验证了NAMPT,SLC11A1,TNC,VIM和SPP1作为LGG中ICB疗效的预测标记.
为LGG患者的免疫疗法选择和预后预测提供了一个框架.

关键词:

生物标志物生物标志物免疫检查站封锁免疫检查站封锁低度质瘤是一种低度的质瘤.新抗原是一种新抗原.

更多相关视频

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.